1-6 of 6
Zachary D. Crees
Close
Sort by
Journal Articles

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Peter Ruminski, Abi Vainstein, Ella Sorani, Allison A. King, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 10432–10433.
https://doi.org/10.1182/blood-2022-165454
Published: 2022
Journal Articles

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Michael J Slade, Abir Khalid, Mark A Fiala, Mariya Liyasova, Mark A Zaydman, Zac McDonald, Julie M Fortier, Sarah Kelley, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, Liqiang Yang, Ravi Vij
Journal: Blood
Blood (2022) 140 (Supplement 1): 4376–4377.
https://doi.org/10.1182/blood-2022-155582
Published: 2022
Journal Articles

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Jacob Edmisson, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Jingyu Xiang, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, John F. DiPersio, Ravi Vij
Journal: Blood
Blood (2022) 140 (Supplement 1): 4295–4296.
https://doi.org/10.1182/blood-2022-169367
Published: 2022
Journal Articles

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Zachary D. Crees, Michael Retting, Reyka G Jayasinghe, Keith E. Stockerl-Goldstein, Abi Vainstein, Ella Sorani, Debby Ickowicz, Liron Shemesh-Darvish, Shaul Kadosh, John F. DiPersio
Journal: Blood
Blood (2021) 138 (Supplement 1): 3816.
https://doi.org/10.1182/blood-2021-144297
Published: 2021
Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Zachary D. Crees, Keith E. Stockerl-Goldstein, Sarah Larson, Árpád Illés, Giuseppe Milone, Massimo Martino, Patrick Stiff, Douglas W. Sborov, Denise L. Pereira, Ivana N. Micallef, Gemma Moreno Jiménez, Gábor Mikala, Maria liz paciello Coronel, Udo Holtick, John W. Hiemenz, Muzaffar H. Qazilbash, Nancy M. Hardy, Tahir Latif, Irene García-Cadenas, Abi Vainstein, Ella Sorani, Irit Gliko-Kabir, Inbal Goldstein, Shaul Kadosh, John F. DiPersio
Journal: Blood
Blood (2021) 138 (Supplement 1): 475.
https://doi.org/10.1182/blood-2021-144296
Published: 2021
Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Zachary D. Crees, Keith E. Stockerl-Goldstein, Michael Retting, Sarah M Larson, Arpad Illes, Giuseppe Milone, Massimo Martino, Patrick Stiff, Douglas W. Sborov, Denise L. Pereira, Ivana N. Micallef, Gemma Moreno Jiménez, Gábor Mikala, Maria Liz Paciello Coronel, Udo Holtick, John W. Hiemenz, Muzaffar H. Qazilbash, Nancy M. Hardy, Tahir Latif, Irene García-Cadenas, Ella Sorani, Liron Shemesh-Darvish, Abi Vainstein, Shaul Kadosh, John F. DiPersio
Journal: Blood
Blood (2021) 138 (Supplement 1): 2849.
https://doi.org/10.1182/blood-2021-146783
Published: 2021